| Prev Close | 86.72 |
| Day Low/High | 86.78 / 87.71 |
| 52 Wk Low/High | 62.66 / 92.99 |
| Avg Volume | 7.69M |
AbbVie Inc. (ABBV)
86.98
NYSE : Health Technology
| Exchange | NYSE |
| Shares Outstanding | 1.48B |
| Market Cap | 128.24B |
| EPS | 3.70 |
| P/E Ratio | 38.04 |
| Div & Yield | 4.72 (4.91%) |
Shire Proposes $30B Deal to Buy Disease Specialist Baxalta
Shire (SHPG) has announced an offer to buy Baxalta (BXLT), a rare disease treatment specialist based in the U.S., for around $30.6 billion in stock.
Price Isn't a Problem for Gilead Sciences
Drugmaker has one of the best showings of earnings season.
Price Isn't a Problem for Gilead Sciences
Drugmaker has one of the best showings of earnings season.
Avoid Gilead Shares for Now
Competition and lower earnings cloud its future.
What to Watch Friday: American Airlines Earnings, New Home Sales
For Friday July 24, TheStreet awaits quarterly financial results from Biogen (BIIB), AbbVie (ABBV), American Airlines Group (AAL), and Spirit Airlines (SAVE).
How to Navigate This Week's Earnings Minefield
Don't make a learning week a gambling week.
What to Watch in the Week Ahead: Apple Earnings, Housing Data
For the week of July 20, TheStreet outlines the key earnings reports and economic data to watch on Wall Street.
Looking for the Next Receptos Is Plain Stupid Right Now
These stocks will be up so high today, that many fans will say "no thanks."
The Stock Market Is Treacherous, Perilous, and Ultra-Rewarding
This market is almost entirely special situation.
3 Dividend Hikes This Week You Should Know About
Duke Energy's recent increase puts its payout at the high end of the industry range.
'GILDed Age' Is Over for Gilead Shares
The biotech's stock has likely peaked, as increased competition awaits in the Hep-C space.
Biotech Moves Are Anything But Crazy
New companies are coming up with major drugs.
AbbVie Is Knocking on the Door Again
The ABBV chart looks constructive, with solid volume and bullish indicators.
Cramer: I'm Buying J&J as It Has the Most Upside of Major Pharmas
Jim Cramer reveals why his Action Alerts PLUS charitable trust portfolio is initiating coverage of Johnson & Johnson (JNJ) on Tuesday.
Deluge of Deals Isn't About to Dry Up
Acquisitions cut into overabundance of companies.
3 Biotechs That Are Worth Buying
Many of these stocks are off to the races.
3 Reasons Not to Be Gloomy About the Stock Market
With a weak dollar, calm oil and tame rates, we're doing fine.
Galapagos Drug in Partnership With AbbVie Looks to Replace HUMIRA
Galapagos (GLPG) is the latest biotech stock to list on the Nasdaq Market with an impressive first day of trading as the stock traded up 20%.
You Can Almost Smell the Euphoria
The market is a very happy place these days, so be careful.
3 Fantastic Pharmaceutical Stocks: Abbvie, Vertex and Biogen
AbbVie is a cheap stock and worries about competition immediately hurting its rheumatoid arthritis drug Humira are overblown, said John Schroer, Portfolio Manager for the AllianzGI Health Sciences Fund.
Janet Yellen, Stock Market Commentator?
It's not the Fed chief's place.
Despite Turmoil, Good Buys Still Exist
Drug makers, Apple and other tech stocks among reasonable bargains.
Apple and Gilead on the Earnings Clock
What to expect and focus on when these two report this week.
Until Next Time ...
The market was a slow-rolling melt-up today as Nasdaq closed at all-time highs and the S&P 500 closed above all-time levels, but just barely. The Russell 2000 underperformed today. Although the indices did not see much movement, there were some big ...
I'm Going to Keep Riding These Horses
Biogen miss no reason to abandon big 4 of Big Pharma.
Gilead May Be the Cure for the Blues
Gilead's Relative Strength Index slope is very strong.
Gilead May Be the Cure for the Blues
Gilead's Relative Strength Index slope is very strong.
